We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.075 | 0.54% | 14.055 | 14.11 | 13.88 | 13.95 | 7,388,630 | 20:37:55 |
From May 2019 to May 2024
By Colin Kellaher
Teva Pharmaceutical Industries Ltd. (TEVA) on Tuesday said it is ending clinical development of fremanezumab in cluster headaches after determining a Phase 3 study in episodic cluster headaches was unlikely to meet its primary endpoint.
The Israeli pharmaceutical company said it is also ending a long-term safety study that was part of the Phase 3 program.
Teva last year discontinued a study arm of the program in chronic cluster headaches for similar reasons.
The U.S. Food and Drug Administration in December approved fremanezumab, marketed as Ajovy, for the preventive treatment of migraine in adults. Teva earlier this month said the European Commission granted similar approval for Ajovy.
Teva said it will continues to explore other uses for fremanezumab, including the treatment of post-traumatic headache.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 23, 2019 10:55 ET (14:55 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
